Bioventus (BVS) reported second-quarter 2026 revenue of $153.2 million, up 4% from the prior-year period. Net income attributable to Bioventus Inc. was $33.4 million, compared with $7.5 million a year earlier, and GAAP diluted earnings were $0.47 per share.
The company reaffirmed its 2026 guidance and said it initiated a review of strategic alternatives after receiving an unsolicited acquisition proposal and other expressions of interest.
- Second-quarter worldwide revenue was $153.2 million, driven by double-digit growth in Pain Treatments.
- GAAP diluted EPS was $0.47, compared with $0.11 in the prior-year period.
- Cash from operations totaled $19.9 million in the quarter.
- Bioventus reaffirmed 2026 net sales guidance of $600 million to $610 million.
- The strategic review may include a sale of the company or continued execution of its standalone plan.
$BVS Insider Trading Activity
$BVS insiders have traded $BVS stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BVS stock by insiders over the last 6 months:
- MICHELLE MCMURRY-HEATH sold 12,000 shares for an estimated $105,439
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BVS Hedge Fund Activity
We have seen 76 institutional investors add shares of $BVS stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HILLSDALE INVESTMENT MANAGEMENT INC. added 401,230 shares (+148.7%) to their portfolio in Q1 2026, for an estimated $3,663,229
- BUCKLEY CAPITAL ADVISORS, LLC removed 322,871 shares (-79.8%) from their portfolio in Q1 2026, for an estimated $2,947,812
- QUBE RESEARCH & TECHNOLOGIES LTD removed 315,985 shares (-70.4%) from their portfolio in Q1 2026, for an estimated $2,884,943
- ENGINE CAPITAL MANAGEMENT, LP added 315,018 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,876,114
- EVERSEPT PARTNERS, LP removed 312,147 shares (-66.2%) from their portfolio in Q1 2026, for an estimated $2,849,902
- ACADIAN ASSET MANAGEMENT LLC added 276,775 shares (+491.3%) to their portfolio in Q1 2026, for an estimated $2,526,955
- AMERICAN CENTURY COMPANIES INC removed 227,988 shares (-26.9%) from their portfolio in Q1 2026, for an estimated $2,081,530
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
